TB Archives – Page 23 of 48 – Treatment Action Group

Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards

December 7, 2018
Chad Cipiti

By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American…

About TAG: The Legacy and Future of Activism to Catalyze the End to HIV/AIDS, Tuberculosis, and Hepatitis C

December 6, 2018
Dorrit Walsh

This two-page brief explains TAG’s mission, gives information about TAG’s origins, describes how we work, and lists some of our many accomplishments since our founding in 1992.

2018 TAG Update

December 4, 2018
Chad Cipiti

I want to thank all of you for the support that enabled the successes TAG achieved this past year. Despite a challenging political climate and continued attacks against those living with or at risk of contracting HIV, tuberculosis (TB), or…

2018 Report on TB Research Funding Trends

December 3, 2018
Chad Cipiti

Global funding for tuberculosis (TB) research climbed to a previously unreported high of USD $772 million in 2017. This marks the second year in a row that funding for TB research and development (R&D) exceeded $700 million.

Rapid Shift From Global To National Purchase of TB Drugs Increases Risk of Stockouts and Use of Drugs of Unknown Quality

October 26, 2018
Chad Cipiti

Global activists at the 49th Union Conference on Lung Health in The Hague opened up a pop-up TB drug warehouse to warn about the dire public health consequences of a rushed shift from Global Fund supported pooled procurement of tuberculosis (TB) drugs and other health products to domestic funding and national procurement systems.

Activists Urge National TB Programs and Treatment Providers To Discontinue Use of Harmful Injectable Agents in TB Treatment

October 25, 2018
Chad Cipiti

Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in treatment regimens for drug-resistant tuberculosis, in favor of newer, safer World Health Organization (WHO)-recommended treatments.

Reality Check: The Price of Bedaquiline

October 16, 2018
Chad Cipiti

Bedaquiline is now recommended as a core part of drug-resistant TB treatment, but price is a major concern to ensuring all who need treatment with bedaquiline receive it. The public has made significant investments in the development and introduction of bedaquiline,…

Right to Science Submission – October, 2018

October 16, 2018
Chad Cipiti

The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).

TB, Human Rights, and Universal Periodic Review

October 12, 2018
Chad Cipiti

Universal Periodic Review (UPR) is a process through which the human rights record of each United Nations member state is reviewed by other countries every five years. As a civil society organization, TAG regularly writes and submits these UPR reports analyzing the TB situations in UN member states, and you can review our UPR reports on this page.

The Tuberculosis Diagnosis Pipeline for Children

October 10, 2018
Chad Cipiti

July 2018 by Lindsay McKenna Existing tests and those under development that are designed to detect tuberculosis (TB) bacteria (see the Tuberculosis Diagnosis Pipeline, coming soon) are suboptimal for children, who often have fewer TB bacteria in their bodies than…